Daiwa Securities Group Inc. Boosts Holdings in Boston Scientific Corporation $BSX

Daiwa Securities Group Inc. boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 11.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 355,299 shares of the medical equipment provider’s stock after buying an additional 36,284 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Boston Scientific were worth $33,878,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. FWL Investment Management LLC purchased a new position in Boston Scientific during the second quarter worth $26,000. Murphy & Mullick Capital Management Corp boosted its stake in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the period. Colonial Trust Co SC boosted its stake in Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 231 shares during the period. Bangor Savings Bank boosted its stake in Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares during the period. Finally, Board of the Pension Protection Fund purchased a new position in Boston Scientific during the fourth quarter worth $29,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BSX has been the subject of several recent analyst reports. Argus raised shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Citigroup dropped their price objective on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, May 28th. Canaccord Genuity Group decreased their target price on Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a research report on Monday. Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a research report on Friday, February 6th. Finally, UBS Group decreased their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.92.

Boston Scientific Stock Down 0.4%

NYSE:BSX opened at $48.66 on Friday. Boston Scientific Corporation has a twelve month low of $47.17 and a twelve month high of $109.50. The company has a market cap of $72.32 billion, a price-to-earnings ratio of 20.36, a price-to-earnings-growth ratio of 0.91 and a beta of 0.56. The stock has a fifty day simple moving average of $58.11 and a 200-day simple moving average of $76.70. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts anticipate that Boston Scientific Corporation will post 3.37 EPS for the current year.

Boston Scientific declared that its Board of Directors has approved a share buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Canaccord reiterated a Buy rating on Boston Scientific, even though it trimmed its price target slightly to $70 from $71, signaling continued confidence in the company’s long-term outlook. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?
• Positive Sentiment: Truist also kept a Buy rating, though it cut its price target to $64 from $85, suggesting analysts still see meaningful upside despite a more cautious valuation view. Benzinga
• Positive Sentiment: The company announced plans for a $138 million medical device distribution facility in Indiana, which should expand operations and add 300 jobs, a sign of ongoing investment in growth and logistics capacity. Boston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs
• Neutral Sentiment: Boston Scientific’s last reported quarter was strong, with revenue of $5.20 billion and EPS of $0.80 beating expectations, but the company also cut guidance due to stronger competition in cardiac devices and slower Watchman growth, creating a mixed fundamental backdrop. How Investors May Respond To Boston Scientific (BSX) Strong Q1 Beat But Cut Guidance On Watchman Growth
• Neutral Sentiment: Recent market commentary noted BSX has been trading above market averages on some sessions, but also lagging some peers, reflecting choppy investor sentiment rather than a clear trend. Boston Scientific Corp. stock underperforms Thursday when compared to competitors despite daily gains
• Negative Sentiment: The repeated reductions in price targets from analysts, including Truist and Canaccord, suggest expectations have reset lower, which can weigh on sentiment even when ratings remain positive. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?

Insider Activity at Boston Scientific

In other news, Director David C. Habiger bought 2,250 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 9,800 shares of company stock worth $554,012 over the last three months. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.